1
|
Tobita S, Kinehara Y, Tamura Y, Kurebe H, Ninomiya R, Utsu Y, Kohmo S, Sato B, Nagai K, Maruoka S, Jokoji R, Koyama S, Tachibana I. Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions. Thorac Cancer 2020; 11:2357-2360. [PMID: 32567218 PMCID: PMC7396382 DOI: 10.1111/1759-7714.13539] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 05/28/2020] [Accepted: 05/30/2020] [Indexed: 01/05/2023] Open
Abstract
The patient in this report was a 57‐year‐old man with metastatic non‐small cell lung cancer (NSCLC). After no response to two lines of systemic chemotherapy, he was treated with nivolumab as third‐line therapy, which resulted in a partial response. After 17 months of nivolumab treatment, he developed bone metastasis in his left femur which was treated with radiation therapy. Nivolumab was restarted after radiation therapy. Four months after radiation therapy, he developed another metastatic lesion in the small intestine which was surgically resected. Because there were no recurrent NSCLC lesions after surgical resection, nivolumab was restarted again. At 18 months after surgery, there were no recurrent NSCLC lesions. Immunohistochemical analysis of peritumoral T lymphocytes showed higher expression of T cell immunoglobulin and mucin domain‐containing protein 3 (TIM‐3) and lymphocyte activation gene 3 (LAG‐3) in recurrent lesions of bone and small intestine than in primary lesions. Upregulation of TIM‐3 and LAG‐3 could be associated with mechanisms of adaptive resistance to nivolumab in this case. Here, we report a successful case of continued nivolumab therapy with remission after local treatments consisting of radiation therapy and surgical resection for oligometastases. Continuation of immune checkpoint inhibitor (ICI) treatment may be worth considering if oligometastases can be controlled. Key points Significant findings of the study We report a successful case of continued nivolumab treatment with remission after local treatment (radiation therapy and surgical resection) for oligometastases. What this study adds Upregulation of T cell immunoglobulin and mucin domain‐containing protein 3 and lymphocyte‐activation gene 3 could be associated with mechanisms of adaptive resistance to nivolumab.
Collapse
Affiliation(s)
- Satoshi Tobita
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| | - Yuhei Kinehara
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| | - Yoshio Tamura
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| | | | | | - Yoshihiko Utsu
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| | - Satoshi Kohmo
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| | - Bunzo Sato
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| | - Kenichi Nagai
- Department of Gastrointestinal Surgery, Nippon Life Hospital, Osaka, Japan
| | | | - Ryu Jokoji
- Department of Pathology, Nippon Life Hospital, Osaka, Japan
| | - Shohei Koyama
- Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
| | - Isao Tachibana
- Department of Medicine, Nippon Life Hospital, Osaka, Japan
| |
Collapse
|
2
|
Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. PLoS One 2019; 14:e0220570. [PMID: 31365588 PMCID: PMC6668842 DOI: 10.1371/journal.pone.0220570] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2019] [Accepted: 07/18/2019] [Indexed: 11/21/2022] Open
Abstract
Background Pembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression ≥50%. However, the association between the efficacy of pembrolizumab and PD-L1 expression levels in patients with PD-L1 expression ≥50% has not been fully elucidated. Methods We retrospectively analyzed patients with advanced NSCLC and a PD-L1 tumor proportion score (TPS) of ≥50% who received pembrolizumab as a first-line therapy at 11 institutions in Japan between February 2017 and January 2018. Patients were divided into TPS 50–89% and TPS 90–100% (ultra-high PD-L1 expression) cohorts. Results In total, 149 patients were included: 99 (66.4%) and 50 (33.6%) patients were in the TPS 50–89% and TPS 90–100% cohorts, respectively. Baseline characteristics were similar between the TPS 90–100% and TPS 50–89% cohorts. The objective response rates (ORR) in the TPS 90–100% and TPS 50–89% cohorts were 58.0% and 46.5%, respectively (p = 0.23). Time to treatment failure (TTF) was longer in the TPS 90–100% cohort than in the TPS 50–89% cohort (hazard ratio [HR]: 0.67, 95% confidence interval (CI): 0.42–1.07; p = 0.09). Although TTF within 120 days after the initiation of pembrolizumab therapy was comparable between both cohorts (p = 0.54), TTF after 120 days was significantly longer in the TPS 90–100% cohort than in the TPS 50–89% cohort (HR: 0.22, 95% CI: 0.06–0.87; p = 0.031). Immune related adverse events of grade 3 or more occurred in 16.0% and 19.2% of patients in the TPS 90–100% and TPS 50–89% cohorts, respectively. Conclusions The patients with an ultra-high PD-L1 expression continued pembrolizumab therapy longer, driven by a reduced risk of treatment failure in the late phase. PD-L1 expression levels might be a predictive biomarker of a first-line immunotherapy benefit in the late phase among NSCLC patients with TPS ≥50%.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antineoplastic Agents, Immunological/therapeutic use
- B7-H1 Antigen/metabolism
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Carcinoma, Non-Small-Cell Lung/metabolism
- Carcinoma, Non-Small-Cell Lung/mortality
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Squamous Cell/drug therapy
- Carcinoma, Squamous Cell/metabolism
- Carcinoma, Squamous Cell/mortality
- Carcinoma, Squamous Cell/pathology
- Female
- Follow-Up Studies
- Humans
- Immunotherapy/mortality
- Lung Neoplasms/drug therapy
- Lung Neoplasms/metabolism
- Lung Neoplasms/mortality
- Lung Neoplasms/pathology
- Male
- Middle Aged
- Prognosis
- Retrospective Studies
- Survival Rate
Collapse
Affiliation(s)
- Ryuya Edahiro
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan
| | - Masaki Kanazu
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan
- * E-mail:
| | - Hiroyuki Kurebe
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan
| | - Masahide Mori
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan
| | - Daichi Fujimoto
- Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
| | - Yoshihiko Taniguchi
- Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan
| | - Hidekazu Suzuki
- Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan
| | - Katsuya Hirano
- Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan
| | - Toshihide Yokoyama
- Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Japan
| | - Mitsunori Morita
- Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan
| | - Yasushi Fukuda
- Department of Respiratory Medicine, Himeji Medical Center, Himeji, Japan
| | - Junji Uchida
- Department of Respiratory Medicine, Osaka General Medical Center, Osaka, Japan
| | - Takeshi Makio
- Department of Respiratory Medicine, Itami City Hospital, Itami, Japan
| | - Motohiro Tamiya
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan
| |
Collapse
|
3
|
Edahiro R, Ishijima M, Kurebe H, Nishida K, Uenami T, Kanazu M, Akazawa Y, Yano Y, Mori M. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report. Thorac Cancer 2019; 10:1276-1279. [PMID: 30964601 PMCID: PMC6500988 DOI: 10.1111/1759-7714.13065] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2019] [Revised: 03/15/2019] [Accepted: 03/19/2019] [Indexed: 12/26/2022] Open
Abstract
A 61-year-old woman with stage IVA lung adenocarcinoma exhibited high PD-L1 expression. Pembrolizumab was administered as second-line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently diagnosed with fulminant type 1 diabetes mellitus and ketoacidosis during the eighth course and insulin treatment was initiated. Pembrolizumab remained effective and was continued for 21 courses, even after the onset of diabetes mellitus. Immune-checkpoint inhibitor treatment can be continued with hormone replacement even after the development of type 1 diabetes mellitus as an immune-related adverse event.
Collapse
Affiliation(s)
- Ryuya Edahiro
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Mikako Ishijima
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Hiroyuki Kurebe
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Kohei Nishida
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Takeshi Uenami
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Masaki Kanazu
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Yuki Akazawa
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Yukihiro Yano
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| | - Masahide Mori
- Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-city, Osaka, Japan
| |
Collapse
|
4
|
Edahiro R, Kurebe H, Nakatsubo S, Hosono Y, Sawa N, Nishida K, Ohara Y, Oshitani Y, Kagawa H, Tsujino K, Yoshimura K, Miki K, Miki M, Kitada S, Mori M. Three Cases of Idiopathic Diffuse Pulmonary Ossification. Intern Med 2019; 58:545-551. [PMID: 30333390 PMCID: PMC6421151 DOI: 10.2169/internalmedicine.0929-18] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Diffuse pulmonary ossification (DPO) is an uncommon diffuse lung disease characterized by metaplastic bone formation in the lung parenchyma and is rarely diagnosed in life. While DPO usually occurs as a secondary disease, idiopathic cases are extremely rare. We describe three cases of idiopathic DPO, two of which were definitively diagnosed by surgical lung biopsy. One case was observed in a 43-year-old man with a history of recurrent pneumothorax who developed pneumothorax after the surgical biopsy. Few reports have described cases of DPO with recurrent pneumothorax; however, pneumothorax should be considered as a potential complication when such patients are encountered.
Collapse
Affiliation(s)
- Ryuya Edahiro
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Hiroyuki Kurebe
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Saeko Nakatsubo
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Yuki Hosono
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Nobuhiko Sawa
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Kohei Nishida
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Yuko Ohara
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Yohei Oshitani
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Hiroyuki Kagawa
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Kazuyuki Tsujino
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Kenji Yoshimura
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Keisuke Miki
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Mari Miki
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Seigo Kitada
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| | - Masahide Mori
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Japan
| |
Collapse
|
5
|
Kurebe H, Edahiro R, Kanazu M, Fujimoto D, Tamiya M, Tamiya A, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T. Clinical outcomes in non–small cell lung cancer patients with ultra-high expression of programmed death ligand-1 treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Uenami T, Ishijima M, Kanazu M, Kurebe H, Edahiro R, Nishida K, Akazawa Y, Yano Y, Yamaguchi T, Mori M. Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression. Ann Transl Med 2018; 6:444. [PMID: 30596074 DOI: 10.21037/atm.2018.10.24] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Recently, the immune checkpoint inhibitor (ICI) pembrolizumab was demonstrated to be superior to platinum doublet chemotherapy in the first-line setting in patients with tumor programmed death-ligand 1 (PD-L1) expression of at least 50%. However, because patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements were not included in that study, the efficacy of pembrolizumab in lung cancers carrying EGFR mutations could not be determined. Here we describe two cases of response to pembrolizumab in EGFR mutated lung adenocarcinoma patients with PD-L1 overexpression. These cases indicate that ICI is an effective treatment for EGFR mutated lung adenocarcinoma patients with PD-L1 overexpression.
Collapse
Affiliation(s)
- Takeshi Uenami
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Mikako Ishijima
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Masaki Kanazu
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Hiroyuki Kurebe
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Ryuya Edahiro
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Kohei Nishida
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Yuki Akazawa
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Yukihiro Yano
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Toshihiko Yamaguchi
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| | - Masahide Mori
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
| |
Collapse
|
7
|
Miki K, Miki M, Yoshimura K, Tsujino K, Kagawa H, Oshitani Y, Ohara Y, Hosono Y, Edahiro R, Kurebe H, Kitada S. Improvement of exertional dyspnea and breathing pattern of inspiration to expiration after bronchial thermoplasty. Allergy Asthma Clin Immunol 2018; 14:74. [PMID: 30386387 PMCID: PMC6205802 DOI: 10.1186/s13223-018-0276-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2018] [Accepted: 07/23/2018] [Indexed: 12/16/2022] Open
Abstract
Background Bronchial thermoplasty (BT) is a bronchoscopic treatment that can ameliorate the symptoms of severe asthma. However, little is known about the mechanism by which BT improves exertional dyspnea without significantly changing the resting pulmonary function in asthmatics. To understand the mechanism, cardiopulmonary variables were investigated using cardiopulmonary exercise testing (CPET) in a patient with severe asthma before and after BT. Case presentation A 57-year-old Japanese man visited our hospital for consultation of the intractable asthma, which we managed with three treatment sessions of BT. Comparison of the findings pre-BT and at 1 year after BT demonstrated that (1) the resting tests for respiration showed no improvement in forced expiratory volume in 1 s, but the forced oscillation technique showed decreases in both inhalation and exhalation respiratory resistance values, and (2) the CPET results showed (i) improvement in exertional dyspnea, exercise endurance, and arterial oxygen saturation at the end of exercise; (ii) that the expiratory tidal volume exceeded the inspiratory tidal volume during exercise, which implied that a sufficient exhalation enabled longer inspiratory time and adequate oxygen absorption; and (iii) that an increase in respiratory frequency could be prevented throughout exercise. Conclusions This case report described a novel mechanism of BT in improving exertional dyspnea and exercise duration, which was brought about by ventilatory improvements related to the breathing pattern of inspiration to expiration.
Collapse
Affiliation(s)
- Keisuke Miki
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Mari Miki
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Kenji Yoshimura
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Kazuyuki Tsujino
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Hiroyuki Kagawa
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Yohei Oshitani
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Yuko Ohara
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Yuki Hosono
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Ryuya Edahiro
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Hiroyuki Kurebe
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| | - Seigo Kitada
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka 560-8552 Japan
| |
Collapse
|
8
|
Uenami T, Ishijima M, Kanazu M, Kurebe H, Edahiro R, Nishida K, Akazawa Y, Yano Y, Yamaguchi T, Mori M. P3.CR-20 The Effect of Pembrolizumab In EGFR Mutated Lung Adenocarcinoma Patients With PD-L1 Overexpression: Two Cases Report. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1999] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
9
|
Yano Y, Kurebe H, Edahiro R, Hosono Y, Nakatsubo S, Nishida K, Sawa N, Ishijima M, Uenami T, Kanazu M, Akazawa Y, Yamaguchi T, Mori M. Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. PLoS One 2018; 13:e0203070. [PMID: 30153300 PMCID: PMC6112658 DOI: 10.1371/journal.pone.0203070] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2018] [Accepted: 08/14/2018] [Indexed: 12/26/2022] Open
Abstract
OBJECTIVES The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated. The aim of the present study was to clarify the clinical benefit of post-nivolumab treatment in such patients. MATERIALS AND METHODS A retrospective review was conducted on patients who received treatment after cessation of nivolumab due to disease progression or adverse events at the Toneyama National Hospital between January 2016 and April 2017. RESULTS Among 64 patients treated with nivolumab, 26 patients received treatment after cessation of nivolumab due to disease progression (n = 21) or adverse events (n = 5). The median age of the patients was 68 years and 19 patients were male. Nineteen patients had performance status (PS) 1 or less at initiation of post-nivolumab treatment. Four, 20, and 2 patients were treated with platinum doublets, a single agent, and molecular targeting agents, respectively. Response rate, disease control rate, and median progression-free survival of first-line post-nivolumab treatment were 34.6% (9 patients), 73.1% (19 patients), and 2.8 months (95% confidence interval [CI]: 1.7-5.2), respectively. Adverse events (≥ grade 3) and treatment cessation were observed in 57.7% (15 patients) and 19.2% (5 patients), respectively. There were no statistically significant differences for the majority of patient characteristics between the groups with (n = 26) and without post-nivolumab treatment. However, PS at cessation of nivolumab and post-progression survival (PPS) after cessation of nivolumab (median PPS: 12.6 vs. 1.4 months, 95% CI: 3.8-14.7 vs. 0.4-2.2) were significantly different between the groups. A multivariate Cox regression analysis showed significant correlation of PS at cessation of nivolumab (hazard ratio [HR]: 0.34, 95% CI: 0.13-0.87) and post-nivolumab treatment (HR: 0.19, 95% CI: 0.08-0.43) with prolonged PPS after nivolumab. CONCLUSION Median post-progression survival in patients with advanced NSCLC who received post-nivolumab treatment was approximately 1 year.
Collapse
Affiliation(s)
- Yukihiro Yano
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
- * E-mail:
| | - Hiroyuki Kurebe
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Ryuya Edahiro
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Yuki Hosono
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Saeko Nakatsubo
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Kohei Nishida
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Nobuyuki Sawa
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Mikako Ishijima
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Takeshi Uenami
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Masaki Kanazu
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Yuki Akazawa
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Toshihiko Yamaguchi
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| | - Masahide Mori
- Department of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka, Osaka, Japan
| |
Collapse
|
10
|
Miki K, Tsujino K, Edahiro R, Kitada S, Miki M, Yoshimura K, Kagawa H, Oshitani Y, Ohara Y, Hosono Y, Kurebe H, Maekura R. Exercise tolerance and balance of inspiratory-to-expiratory muscle strength in relation to breathing timing in patients with chronic obstructive pulmonary disease. J Breath Res 2018; 12:036008. [PMID: 29321341 DOI: 10.1088/1752-7163/aaa6db] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
RATIONALE Little is known about the applicability of respiratory muscle training based on exertional pathophysiological conditions in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the relationship between breathing timing and exertional responses, as well as whether exertional changes in the inspiratory duty cycle (Ti/Ttot) affect pathophysiological conditions, including respiratory muscles. METHODS Forty-five stable COPD patients (mean age: 71.2 years, severe and very severe COPD: 80%) were evaluated based on exertional cardiopulmonary function and respiratory muscle strength. To compare exertional responses and the balance of inspiratory-to-expiratory muscle strength, the patients were divided into two groups according to whether the Ti/Ttot increased (Ti/Ttot-increased group: resting Ti/Ttot ≤ peak Ti/Ttot, n = 21) or decreased during exercise (Ti/Ttot-decreased group: resting Ti/Ttot > peak Ti/Ttot, n = 24). RESULTS At peak exercise, the Ti/Ttot was positively correlated with minute ventilation ([Formula: see text] E), and oxygen uptake ([Formula: see text]) in all patients. No significant differences were seen in breathing frequency, tidal volume, or [Formula: see text] E at peak exercise between the two groups. Compared with the Ti/Ttot-increased group, the Ti/Ttot-decreased group had significantly lower mean values of [Formula: see text] and ΔFO2 (the inspired minus expired oxygen concentration) at peak exercise, and significantly higher mean values of the absolute ratio of maximal inspiratory pressure/maximal expiratory pressure. CONCLUSIONS The exertional change of breathing timing affected exercise tolerance and the balance of inspiratory-to-expiratory muscle strength; this finding might be helpful in making the contradictory choice of managing COPD patients with inspiratory or expiratory muscle training.
Collapse
Affiliation(s)
- Keisuke Miki
- Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, 5-1-1 Toneyama, Toyonaka, Osaka, 560-8552, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kano S, Nishida K, Kurebe H, Nishiyama C, Kita K, Akaike Y, Kajita K, Kurokawa K, Masuda K, Kuwano Y, Tanahashi T, Rokutan K. Oxidative stress-inducible truncated serine/arginine-rich splicing factor 3 regulates interleukin-8 production in human colon cancer cells. Am J Physiol Cell Physiol 2014; 306:C250-62. [DOI: 10.1152/ajpcell.00091.2013] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Serine/arginine-rich splicing factor 3 (SRSF3) is a member of the SR protein family and plays wide-ranging roles in gene expression. The human SRSF3 gene generates two alternative splice transcripts, a major mRNA isoform ( SRSF3-FL) encoding functional full-length protein and a premature termination codon (PTC)-containing isoform ( SRSF3-PTC). The latter is degraded through nonsense-mediated mRNA decay (NMD). Treatment of a human colon cancer cell line (HCT116) with 100 μM sodium arsenite increased SRSF3-PTC mRNA levels without changing SRSF3-FL mRNA levels. A chemiluminescence-based NMD reporter assay system demonstrated that arsenite treatment inhibited NMD activity and increased SRSF3-PTC mRNA levels in the cytoplasm, facilitating translation of a truncated SRSF3 protein (SRSF3-TR) from SRSF3-PTC mRNA. SRSF3-TR lacked two-thirds of the Arg/Ser-rich (RS) domain whose phosphorylation state is known to be crucial for subcellular distribution. SRSF3-FL was localized in the nucleus, while overexpressed SRSF3-TR was diffusely distributed in the cytoplasm and the nucleus. A part of SRSF3-TR was also associated with stress granules in the cytoplasm. Interestingly, treatment of HCT116 cells with a small interference RNA specifically targeting SRSF3-PTC mRNA significantly attenuated arsenite-stimulated induction of c-JUN protein, its binding activity to the AP-1 binding site (−126 to 120 bp) in the interleukin (IL)-8 gene promoter, and AP-1 promoter activity, resulting in significant reduction of arsenite-stimulated IL-8 production. Our results suggest that SRSF3-TR may function as a positive regulator of oxidative stress-initiated inflammatory responses in colon cancer cells.
Collapse
Affiliation(s)
- Shizuka Kano
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Kensei Nishida
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Hiroyuki Kurebe
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Chihiro Nishiyama
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Kentaro Kita
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Yoko Akaike
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Keisuke Kajita
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Ken Kurokawa
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Kiyoshi Masuda
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Yuki Kuwano
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Toshihito Tanahashi
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | - Kazuhito Rokutan
- Department of Stress Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| |
Collapse
|